---
figid: PMC10340792__cancers-15-03506-g002
figtitle: Targeting transcription factor YY1 for antitumor therapy
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10340792
filename: cancers-15-03506-g002.jpg
figlink: /pmc/articles/PMC10340792/figure/F2
number: F2
caption: 'Targeting transcription factor YY1 for antitumor therapy. (A) DETA-NONOate
  inhibits YY1 binding to the promoter. (B) Betulinic acid inhibits YY1 through cannabinoid-receptor-dependent
  disruption of microRNA-27a:ZBTB10. (C) JAC1 targets YY1-mediated JWA/p38 signaling
  to inhibit tumor proliferation. (D) YY1BM inhibits the interaction between YY1 and
  the androgen receptor, which in turn decreases expression of eEF2K through the AR
  signaling pathway. (E) Synthetic peptides with the OPB domain disrupt the regulation
  of YY1 by competitive binding. (F) Antibody-based inhibition of YY1 through inhibition
  of the NF-κB signaling pathway. (G) Nucleic-acid-based inhibition of YY1. (H) CRISPR/Cas9
  genome editing of YY1. (I) Role of YY1 in immunotherapy based on CAR-T cells. AKT:
  protein kinase B; AR: androgen receptor; BRD2/4: bromodomain-containing protein
  2/4; CAR: chimeric antigen receptor; CAR-T cell: chimeric antigen receptor T cell;
  CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; Cas9: CRISPR-associated
  protein 9; COX-2: cyclooxygenase 2; DETA-NONOate: diethylenetriamine NONOate; EGFR:
  epidermal growth factor receptor; eEF2K: eukaryotic elongation factor 2 kinase;
  ErbB2: erb-b2 receptor tyrosine kinase 2; Fas: Fas death receptor; HSF1: heat shock
  factor 1; IL-2: Interleukin 2; JWA: ADP ribosylation factor like GTPase 6 interacting
  protein 5 (ARL6IP5); LINC00278: Y-linked long noncoding RNA 278; NO: nitric oxide;
  OPB: oncoprotein binding domain; PD-1: programmed death 1; PD-L1: programmed death
  ligand 1; PFKP: phosphofructokinase, platelet; p38: p38 mitogen-activated protein
  kinase; sgRNA: single guide RNA; TSA: tumor-specific antigen; TRAIL: tumor necrosis
  factor related apoptosis-inducing ligand; YY1BM: YY1-blocking micropeptide; ZBTB10:
  zinc-finger and BTB domain containing 10'
papertitle: 'Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies
  and Future Directions'
reftext: Rendy Hosea, et al. Cancers (Basel). 2023 Jul;15(13).
year: '2023'
doi: 10.3390/cancers15133506
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: yin yang 1 (YY1) | YY1-targeted therapy | clinical implications | antitumor
  therapy | drug resistance
automl_pathway: 0.9189495
figid_alias: PMC10340792__F2
figtype: Figure
redirect_from: /figures/PMC10340792__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10340792__cancers-15-03506-g002.html
  '@type': Dataset
  description: 'Targeting transcription factor YY1 for antitumor therapy. (A) DETA-NONOate
    inhibits YY1 binding to the promoter. (B) Betulinic acid inhibits YY1 through
    cannabinoid-receptor-dependent disruption of microRNA-27a:ZBTB10. (C) JAC1 targets
    YY1-mediated JWA/p38 signaling to inhibit tumor proliferation. (D) YY1BM inhibits
    the interaction between YY1 and the androgen receptor, which in turn decreases
    expression of eEF2K through the AR signaling pathway. (E) Synthetic peptides with
    the OPB domain disrupt the regulation of YY1 by competitive binding. (F) Antibody-based
    inhibition of YY1 through inhibition of the NF-κB signaling pathway. (G) Nucleic-acid-based
    inhibition of YY1. (H) CRISPR/Cas9 genome editing of YY1. (I) Role of YY1 in immunotherapy
    based on CAR-T cells. AKT: protein kinase B; AR: androgen receptor; BRD2/4: bromodomain-containing
    protein 2/4; CAR: chimeric antigen receptor; CAR-T cell: chimeric antigen receptor
    T cell; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; Cas9: CRISPR-associated
    protein 9; COX-2: cyclooxygenase 2; DETA-NONOate: diethylenetriamine NONOate;
    EGFR: epidermal growth factor receptor; eEF2K: eukaryotic elongation factor 2
    kinase; ErbB2: erb-b2 receptor tyrosine kinase 2; Fas: Fas death receptor; HSF1:
    heat shock factor 1; IL-2: Interleukin 2; JWA: ADP ribosylation factor like GTPase
    6 interacting protein 5 (ARL6IP5); LINC00278: Y-linked long noncoding RNA 278;
    NO: nitric oxide; OPB: oncoprotein binding domain; PD-1: programmed death 1; PD-L1:
    programmed death ligand 1; PFKP: phosphofructokinase, platelet; p38: p38 mitogen-activated
    protein kinase; sgRNA: single guide RNA; TSA: tumor-specific antigen; TRAIL: tumor
    necrosis factor related apoptosis-inducing ligand; YY1BM: YY1-blocking micropeptide;
    ZBTB10: zinc-finger and BTB domain containing 10'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - YY1
  - SKIL
  - SBNO2
  - SBNO1
  - CNR1
  - CNR2
  - HSCB
  - ARL6IP5
  - HSF1
  - NR5A1
  - MIR27A
  - ZBTB10
  - FAS
  - FASN
  - AKT1
  - AKT2
  - AKT3
  - LINC00278
  - CRK
  - MAPK14
  - MAPK1
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - AR
  - ERBB2
  - CD80
  - MS4A1
  - KRT20
  - CSE1L
  - CTNND1
  - BCAR1
  - TMX2-CTNND1
  - PFKP
  - TNFSF10
  - NFKB1
  - TNFRSF10B
  - CASR
  - CXADR
  - PRKAR1A
  - SPG7
  - NR1I3
  - TRIM13
  - CXADRP1
  - CARTPT
  - EEF2K
  - MIR186
  - MIR215
  - MIR381
  - MIR544A
  - MIR635
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - PRDX2
  - PTGS2
  - EGFR
  - -SH
  - Betulinic acid
  - Glucose
  - TSA
---
